Lv11
40 积分 2024-07-01 加入
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
2天前
已完结
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
2天前
已完结
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement
2天前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
2个月前
已完结
FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies
3个月前
已完结
Effect of FGFR Alteration on Prognosis in 1963 Urothelial Carcinoma Patients with Immune Checkpoint Inhibitors: Implying Combination of FGFR Inhibitor and Immunotherapy for FGFR-Altered Urothelial Carcinoma
3个月前
已完结
FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies
3个月前
已完结
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
3个月前
已完结
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
4个月前
已完结
A Randomized Trial of Pharmacological Ascorbate, Gemcitabine, and Nab-Paclitaxel for Metastatic Pancreatic Cancer
4个月前
已完结
皖公网安备34019202002308
